Treatment of the Diabetic Heart Failure Patient

Published: 01 July 2020

  • Views:

    Views Icon 550
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes with consideration to new data emerging from SGLT2 inhibitors and GLP-1 Receptor Agonists.

This discussion was supported by an unrestricted educational grant from Novo Nordisk.

More from this programme

Part 1

Diabetes and Heart Failure Outcomes

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes.

Part 2

SGLT2 Inhibitors in Heart Failure

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes.

Part 3

GLP-1 Receptor Agonists in Heart Failure

Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss the potential benefits of glucagon-like peptide 1 (GLP1) receptor agonists for patients with heart failure. They summarise trials that looked into novel antidiabetic agents to date (FIGHT, HARMONY and LIVE). Dr Kosiborod reviews the latest guidelines reflecting on the data. Prof Petrie outlines the potential mechanism behind the benefits of GLP1 receptor agonists in MACE-like events. They discusses the role of novel antidiabetic agents in the treatment of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.

Faculty Biographies

Mikhail Kosiborod

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile
Mark Petrie

Mark Petrie

Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)

Prof Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK. Prof Petrie started his studies as an undergraduate at Edinburgh University, before training in cardiology in Glasgow. He worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016.

Prof Petrie's research interests focus on diabetes and cardiovascular disease in heart failure, structural intervention and revascularization in heart failure, peripartum cardiomyopathy, microvascular disease in heart failure with preserved ejection fraction, postmyocardial infarction cardiac remodeling, iron in heart failure, and cardio-oncology. While Prof Petrie has many research interests, he also takes pleasure in mentoring future high-caliber cardiologists and has supervised many outstanding individuals during their PhDs and MDs.

View full profile